John H. Ford
Deep value, special situations

Senesco: Near-Term Catalyst Could Double Shareprice

I initiated coverage on Senesco (SNTI) four months ago when it was trading at $3. Shares rose above $7, but have since retreated. This provides an ideal opportunity for investors because since my last article, 2 positive events have occurred:

Number 1: Senesco just reported excellent data for cohort 3 of the current clinical trial. This milestone event takes Senesco one step closer to addressing the $75 billion cancer drug market.

Number 2: Opko's (NYSEMKT:OPK), Dr. Phillip Frost just initiated a 9.99% position in Senesco. As some of my readers know, all my Dr. Frost investments have provided returns above 100%. For example, soon after Dr. Frost initiated a position in MusclePharm (OTCQB:MSLP), the stock went...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details